Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > 16.5 cents close today
View:
Post by riverrrow on Jul 18, 2024 4:31pm

16.5 cents close today

How much longer will TLT benefactors continue to fund TLT to keep it going after shelling out 22 cents a share which are now trading at 16.5 cents.  Does anyone really believe a second tranche will be filled at 22 cents?
Comment by Legit62 on Jul 18, 2024 4:57pm
I can guarantee funds will stop if we do not get any news shortly, a second tranche would have been informed by now, who wants to lose money??
Comment by Alamir1111 on Jul 18, 2024 5:06pm
April's pp 17or18 participants  750000$ JULYS pp 18 participants 775000$..pretty consistent
Comment by Dumbeldorfwhite on Jul 18, 2024 4:59pm
My guess is the 2nd tranche contigent upon BTD status being approved
Comment by Kayz88 on Jul 18, 2024 5:58pm
I don't think anything will happen without the BTD status approval. 
Comment by Alamir1111 on Jul 18, 2024 6:04pm
Btd is a nice thing to have but it's not necessary for the final approval est timeline 2026
Comment by Kayz88 on Jul 18, 2024 9:57pm
No, it's not necessary for the final approval. It's absolutely necessary to keep this company afloat. It's a rubberstamp that has the highest probability to raise the stock price so they can raise actual money. If they keep with these small PPs once per quarter, that's another 8 quarters, that's 8 more raises, 8 times more dilution. 
Comment by StevenBirch on Jul 18, 2024 5:06pm
No one is funding this out of the goodness of their heart and I don't know how much they will raise in the next tranche but the volume usually picks up when these PPs are about to close. And again if people are in fact selling so they can take part the buyers aren't going to bid it up, they will make the seller(s) come to them. There always seems to be someone willing to buy lower down ...more  
Comment by 2b7f6fab on Jul 18, 2024 9:35pm
No it didn't close at 16.5 cents today.  The final 26,000 shares traded at 17 cents. https://www.stockwatch.com/Quote/Detail?C:TLT
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250